Week Ending August 22, 2022

“In locally advanced non–small cell lung cancer (NSCLC), immunotherapy consolidation with the PD-L1 inhibitor durvalumab improved overall survival in the PACIFIC trial,1 thus leading to its use after chemoradiotherapy as a standard of care. Real-world evidence of durvalumab’s effect on overall and progression-free survival, however, has been limited, as have assessments of treatment patterns after completion or discontinuation of durvalumab.”
“In an interview with Targeted Oncology, Brandon Sheffield, MD, discussed relevant biomarkers for testing in patients with non–small cell lung cancer, and the cost-effectiveness of single-gene test vs next-generation sequencing.”
“During a Targeted Oncology case-based roundtable event, Rafael Santana-Davila, MD, discussed the data supporting the use of immunotherapy for patients with extensive-stage small cell lung cancer.”
“Informed consent forms for interventional oncology clinical trials are often lengthy and written at too high of a reading level for some patients, making it hard for them to weigh the decision to participate, according to study results.”
“Early diagnosis can make a huge difference in outcomes for lung cancer patients, and screening is particularly important for patients who are considered high-risk. But new data show that these patients are largely unaware of their screening options—and even those who are aware of them aren’t necessarily planning to pursue them.”
“For many people with higher risks of developing cancer, the discovery of a nodule in the lung usually means undertaking a diagnostic journey to determine if it’s malignant or benign through invasive tissue biopsies, exams and other tests.”
“— Opinions differ as to whether genetic testing for all patients is ready for prime time”
“Most women with lung cancer reported some degree of sexual dysfunction following diagnosis, according to study results presented during International Association for the Study of Lung Cancer World Conference on Lung Cancer.”
“In 2020, lung cancer was the second most diagnosed cancer and the leading cause of cancer-related deaths globally, representing 11.4% of all new cancer diagnoses and 18% of all cancer-related deaths.”